<DOC>
	<DOCNO>NCT01057667</DOCNO>
	<brief_summary>This equally randomize ( 1:1 ) , double-blind , parallel arm study ass safety antiviral efficacy RO5024048 add standard Pegasys ( peginterferon alfa-2a ) plus Copegus ( ribavirin ) therapy patient chronic hepatitis C genotype 1 4 . Patients arm A receive RO5024048 ( 1000mg orally twice daily ) 24 week addition Pegasys ( 180 microgram sc weekly ) Copegus ( 1000mg 1200mg orally daily ) . Patients achieve rapid virological response ( RVR ) week 4 , sustain week 22 , stop treatment week 24 ; non-RVR patient continue treatment Pegasys Copegus another 24 week week 48 . Patients arm B receive standard treatment Pegasys ( 180 microgram sc weekly ) Copegus ( 1000mg 1200mg orally daily ) 48 week . Anticipated time study treatment 48 week . Target sample size &lt; 200 .</brief_summary>
	<brief_title>A Study RO5024048 Combination With Pegasys ( Peginterferon Alfa-2a ) Copegus ( Ribavirin ) Patients With Chronic Hepatitis C Genotype 1 4</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , 1870 year age hepatitis C , genotype 1 4 , 6 month duration treatmentna√Øve negative pregnancy test ; female patient childbearing age male patient female partner childbearing age must use two form contraception treatment follow last dose ribavirin accordance locally approve label ribavirin pregnant breast feeding female male partner pregnant female previous interferon ribavirin base therapy investigational antiHCV agent systemic antiviral therapy establish perceived activity HCV &lt; /=3 month prior first dose study drug hepatitis A B , HIV infection history evidence medical condition associate chronic liver disease HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>